This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer. In a prospective study Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients scheduled for trastuzumab treatment at Odense University Hospital, will be offered advanced echocardiographic examination, test of bio-markers and genetic markers for the purpose of investigating if early identification of patients in particular risk of developing heart failure is feasible.
Study Type
OBSERVATIONAL
Enrollment
45
Odense University Hospital
Odense C, Denmark
Global longitudinal strain by two dimentional speckle tracking.
Time frame: Change in outcome from initiation of trastuzumab treatment and after 3,6, and 9 month.
Ratio between the mitral E velocity and early diastolic maximum global strain rate (E/SRE).
Time frame: Change in outcome from initiation of trastuzumab treatment and after 3,6, and 9 month.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.